Brise Pharma Funding: $48M Raised, Series A (2024)
Brise Pharma is based in Shanghai, China. It has raised $48M in total funding. Latest round: Series A.
Brise Pharma funding overview
Brise Pharma is based in Shanghai, China. Brise Pharma has raised $48M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in April 2024. The round record for Brise Pharma runs through 2024; nothing later has been disclosed. Investors on record include Shunxi Fund, Cnfuel Capital, Vinner Therapeutics, Qiming Venture Partners, BioTrack Capital, Sherpa Healthcare Partners and 1 others. 7 distinct backers are named across the disclosed rounds.
Brise Pharma has raised $48M in total disclosed funding across the rounds on record.
Who has invested in Brise Pharma?
Shunxi Fund, Cnfuel Capital, Vinner Therapeutics, Qiming Venture Partners, BioTrack Capital, Sherpa Healthcare Partners are named among the investors backing Brise Pharma.
What was the latest Brise Pharma funding round?
The most recent disclosed round is a Series A, announced in April 2024.
Where is Brise Pharma based?
Brise Pharma is based in Shanghai, China.
When did Brise Pharma last raise?
The last disclosed Brise Pharma round closed in April 2024 at Series A.
Every Brise Pharma figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Shanghai at a similar stage.
